ROS THERAPEUTICS

OPTIMIZING THE TREATMENT EXPERIENCE FOR CHILDREN WITH JIA AND OTHER AUTOIMMUNE AND CHRONIC INFLAMMATORY CONDITIONS 

About us

ROS Therapeutics is a development stage pharmaceutical company committed to optimize the treatment experience and address unmet needs of children with Juvenile Idiopathic Arthritis (JIA) and other autoimmune and chronic inflammatory conditions through an innovative proprietary best-in-class orally delivered methotrexate therapy; Trexior™.


Methotrexate (MTX) is a cornerstone treatment for JIA, one of the most common childhood diseases as well as for rheumatoid arthritis (RA), a common autoimmune inflammatory disease of adults. 


Since the early 90’ies, MTX has had a secure place in the treatment of these diseases and has been shown to have a synergistic relationship with biological therapies. 


Several of the shortcomings of existing

methotrexate therapies, whether oral or injections, are sought overcome with Trexior.

 
photo-1528559955347-0fc66a0cbdcb.jfif

News

March 01, 2021

October 5, 2020

July 01, 2021

Leadership

Hanne Damgaard.jpg

Hanne Damgaard Jensen

Chief Executive Officer,

Board Member

ricki boye.jpg

Ricki Boye

Board Member

ChristianGunni.jpg

Christian Gunni Pedersen

Chief Financial Officer

Morten Sandlykke.jpg

Morten Sandlykke

Board Member

UlrikSpork.jpg

Ulrik Spork

Co-founder, Chairman

Medical Advisors

 Troels Herlin

Kristian Stengaard-Pedersen

CONTACT US

ROS Therapeutics ApS, Ole Maaløes vej 3, 2200 Copenhagen N, Denmark